GE HealthCare Technologies (GEHC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

GE HealthCare Technologies

NasdaqGS•Healthcare•Medical Devices

$64.45+0.95(0.02%)Pre-market

Market Cap

$29.26B

P/E

18.4x

P/S

1.4x

P/B

2.7x

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Profitability (15/25); weakest: Growth (10/25).

Profitability15/25

Growth10/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality11/25

Strengths

Improving marginsNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.6x5y range 12.2x – 26.2x

Currently near its 19-quarter median.

P/S · 1.5x5y range 1.4x – 2.2x

Currently near its 19-quarter median.

P/B · 2.7x5y range 1.6x – 5.6x

Currently below its 19-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 7.8% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $29.26B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $20.24B
Q. Revenue: $5.29B
TTM EBITDA: $3.48B
TTM Op. Income: $2.57B
Q. Op. Income: $739.00M
TTM Net Income: $1.59B
Q. Net Income: $573.00M
EPS: N/A
Shares Out.: $454.00M

$20.24B in TTM revenue grew 1.4% YoY, reaching $5.29B last quarter. TTM EBITDA of $3.48B and TTM operating income of $2.57B show growth is flowing through to the bottom line. TTM net income of $1.59B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 18.0%
Op. Margin: 14.0%
Net Margin: 10.8%

Op. margin of 14.0% is up 0.9% YoY — cost efficiency is improving. Net margin at 10.8% Over the past year, operating margin is up 7% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 18.6x
P/S Ratio: 1.5x
P/B Ratio: 2.7x

At 18.6x P/E, the stock trades within typical market levels. P/S of 1.5x and P/B of 2.7x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $37.25B
Cash: $2.10B
Long-Term Debt: $10.09B
Book Value: $10.97B
D/E Ratio: 0.9
Debt/EBITDA: 10.6

With $37.25B in assets and $10.09B in long-term debt, D/E is 0.9and book value is $10.97B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 8% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

TTM Free Cash Flow: $895.00M
FCF Margin: 4.4%
FCF / Net Income: 0.6

TTM FCF of $895.00M. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 43% — a weakening trend.